STVN stock icon

Stevanato
STVN

$21.67
1.59%

Market Cap: 5.91B

 

About: Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Employees: 5,635

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 3 analysts
0
News positive %
of 17 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 2 (+2) [Q1 2024]

95% more call options, than puts

Call options by funds: $230K | Put options by funds: $118K

94% more repeat investments, than reductions

Existing positions increased: 66 | Existing positions reduced: 34

74% more capital invested

Capital invested by funds: $945M [Q4 2023] → $1.64B (+$697M) [Q1 2024]

70% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 20

45.13% more ownership

Funds ownership: 101.56% [Q4 2023] → 146.69% (+45.13%) [Q1 2024]

11% more funds holding

Funds holding: 132 [Q4 2023] → 146 (+14) [Q1 2024]

Research analyst outlook

3 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$22
2%
upside
Avg. target
$30
38%
upside
High target
$38
75%
upside

3 analyst ratings

positive
33%
neutral
67%
negative
0%
Morgan Stanley
Drew Ranieri
2%upside
$22
Equal-Weight
Maintained
15 Jul 2024
Morgan Stanley
Drew Ranieri
38%upside
$30
Equal-Weight
Maintained
22 Apr 2024
Stephens & Co.
Jacob Johnson
75%upside
$38
Overweight
Reiterated
25 Mar 2024

Financial journalist opinion

Based on 17 articles about STVN published over the past 30 days